2022 European Sample Management Symposium

The SLAS 2022 European Sample Management Symposium course package contains 9 presentations.

Based on presenter permission, 9 of the 11 total podium presentations are available on-demand. The SLAS Scientific Program Committee selects conference speakers based on the innovation, relevance and applicability of research as well as those that best address the interests and priorities of today’s life sciences discovery and technology community. All presentations are published with the permission of the presenters.

Nicolas Zorn, Ph.D.

Head Compound Library Enhancement and Logistics

Hoffmann La Roche

Nicolas Zorn is currently the head of the Compound Library Enhancement and Logistics team at Roche pRED in Basel within The Small Molecule Research, Lead Discovery organization. Nicolas is an Organic Chemist by training (Ph.D. at the University of Paris 6, PostDoc at Indiana University, US) and has worked for 10 years supporting and driving projects in several disease areas as medicinal chemist and computational chemist at Merck MDS in the USA, then Roche in Switzerland. In the last four years, he has led the Compound Library Enhancement and Logistics team in Basel where all samples are processed and distributed for Small Molecule Research in pRED.

Toby Winchester, Ph.D.

Automation Product Manager, Business Application Consultant Team Leader

Titian Software Ltd.

Toby Winchester spent 17 years at Pfizer, first as a senior scientist and then as sample logistics manager supporting diverse SAR project requirements. He joined Titian Software in 2011 and is now product manager for automation integrations and Mosaic SampleBank. Mosaic is the leading sample management software solution for life science laboratories.

Charlotte L. Baker, Ph.D.

Senior Research Scientist


Dr Charlotte Baker, Senior Scientist, Compound Synthesis and Management, Discovery Sciences, AstraZeneca, Gothenburg, Sweden. Eight years of experience developing and driving drug discovery projects in an industrial and academic setting. Currently optimising existing compound management processes for small molecules by creating tools and queries with SQL as well as setting up new work flows on our aqueous platform for oligonucleotides and synthetic biology. Specialist user of Mosaic (LIMS), Beckman Access, Beckman Biomek, Azenta Sample Store and Tecan Fluent. In my free time I enjoy running, cycling, swimming and outdoor adventures.

Alex Mueller, Ph.D.

Data and Decision Scientist

F. Hoffmann-La Roche Ltd.

Ronny Baber, Ph.D.

Head of the Biobank

Leipzig Medical Biobank - University Leipzig

Ronny Baber (PhD) is the Head of the Leipzig Medical Biobank and works in the Institute of Laboratory Medicine, Clinical Chemistry, and Molecular Diagnostics at the University Hospital Leipzig. Since 2010 he is the head of the LIFE-Biobank (now part of the Leipzig Medical Biobank) and the LIFE-Preanalytical laboratory (since 2014) in the Leipzig Research Center for Civilisation Diseases (LIFE). Dr. Baber is a member of the working group in the German Institute for Standardization (DIN) which supports the ISO TC 276 responsible for the ISO norm 20387 on biobanking and BBMRI-ERIC workgroups for the evaluation of CEN standards. He is also member of the Steering Committee and different working groups (e.g. education, stakeholder, public relations) in the “German Biobank Alliance” (GBA) initiated and coordinated by BBMRI.de trying to link GBA biobanks to the BBMRI-ERIC infrastructure. As chair of the Education Committee he is also part of the executive board of the European, Middle Eastern & African Society for Biopreservation and Biobanking (ESBB).

Michael Gray, B.Sc.

Principal Investigator, Sample Management UK Team Leader


Mike Gray, B.Sc. (Hons) GlaxoSmithKline, UK Principal Investigator, Sample Management UK Team Leader Mike Gray received an honours degree in Applied Biology (Pharmacology) from the University of Hertfordshire in 1996. He joined the Compound Management group at SmithKline Beecham in 1997 and over the past 25 years has performed a variety of roles in support of GlaxoSmithKline’s drug discovery initiatives from early discovery to clinical candidate selection. For 12 of these years Mike managed the solid compound collection and shipping operations in the UK. He was co-author of the book, Management of Biological and Chemical Samples for Screening Applications (edited by Mark Wigglesworth and Terry Wood). Mike is a qualified Project Manager (Prince2) and has been involved in numerous modernisation and development projects during his career, he is currently the Team Leader for Lead Optimisation at the GlaxoSmithKline Medicines Research Centre in the UK.

Wolfgang Fecke, Ph.D

Director General


Wolfgang is the Director of the European Research Infrastructure for chemical biology, EU-OPENSCREEN. He obtained his PhD in 1994 at the Heinrich-Heine University in Düsseldorf on the function of protein complexes in mitochondria. After a postdoctoral fellowship at Columbia University, he worked for the next 20 years as scientist and group leader for Novartis and UCB as well as for two biotech companies. During that time in Germany, the UK and Italy, he was involved in drug discovery programs for cancer, CNS and inflammatory disease therapeutics, always with the focus on assay development, high throughput screening and lead profiling. He returned to academia in 2015, supporting the translational Discovery Science group at the VIB institute in Belgium. In 2018, he was appointed director of EU-OPENSCREEN in Berlin. He is also the coordinator of a large EU-funded project and as chair of the European Life Science Research Infrastructure Strategy Board.

Steven van Helden, Ph.D

Pivot Park Screening Centre

Steven van Helden studied chemistry at Utrecht University and, after obtaining his Ph.D. , worked in various roles in pharmaceutical industry for 20 years. Since 2003 he has been responsible for High Throughput Screening (HTS) operations and strategy at Organon/MSD. After the closure of those research facilities he developed a business plan for continuation of the screening activities in Oss, The Netherlands. This led to the formation of the Pivot Park Screening Centre (PPSC) and a central role of this company in the European Lead Factory. Steven is now Chief Technology Officer at PPSC.

Greg Prikler

Director of Business Development


Greg Prikler received his Master’s degree at the Budapest University of Technology as a Pharmaceutical Engineer. Before joining Mcule, he worked as an organic chemist in Budapest, Hungary, and in Zlin, Czech Republic. Greg is the Director of Business Development at Mcule and leading the Custom Solutions Engineering team of chemists, biologists, and cheminformatics professionals. He is managing the business aspects of internal and external development projects related to cheminformatics and compound sourcing. He is responsible for developing strategic solutions to business challenges across a wide range of relationships in drug discovery, research, development, and commercialization.

Yurii Moroz, Ph.D.


Chemspace LLC

Yurii Moroz received PhD from Kyiv National Taras Shevchenko University. He did a postdoc at Tufts and Syracuse University. After returning to Ukraine, Yurii joined Enamine as a scientific advisor to leads their efforts in building synthetically accessible chemical space. Yurii also serves as the CEO of Chemspace, a marketplace for small molecules with the largest catalog to search and buy from.


It's All About Products! How New Automation and Workflow Concepts Influence our Business
Open to view video.  |   Closed captions available
Open to view video.  |   Closed captions available
Collaboration in Sample Management
Open to view video.  |   Closed captions available
Open to view video.  |   Closed captions available
Automation and Training for Research Sample Supply AND Sample Management/Collections
Supply chain solutions to support accelerated lead optimisation
Open to view video.  |   Closed captions available
Open to view video.  |   Closed captions available With the aim to deliver drugs to patients faster, AstraZeneca (AZ) has a high focus on accelerating the design-make-test-analyse (DMTA) cycle from lead generation identification to candidate drug nomination, enabling projects to advance faster and close chemistry design cycles quicker. Since 2020 this has been performed globally by generating data from primary structure activity relationship (SAR) assays twice weekly to meet a 5-day turnaround time from physical sample availability. From 2022, the accelerated SAR strategy has been combined with in vitro DMP, running metabolic stability assays twice weekly to enable faster access to all critical data for design cycle decision making. AZ's Compound Management team (CM) has worked collaboratively across involved groups along the supply chain to minimise turnaround time of sample data while keeping sustainable operations. New compounds are solubilised and pushed to the two other AZ R&D testing sites within 24h of receipt by CM (compounds from local synthesis as well as shipments from CROs) enabling screening scientists to be aligned with the latest compounds available locally and ready for testing (stock solution to assay ready plates). Sample process improvements and new software solutions have been implemented to streamline assay ready plate delivery, such as optimisation of sample storage allocation, picking samples ahead of order placement, as well enabling a sample mixtures ordering feature in our LIMS (Mosaic).
Recent chemogenomics efforts at Roche
Open to view video.  |   Closed captions available
Open to view video.  |   Closed captions available This talk will give a brief overview on the topic of chemogenomics and present the recent efforts that were conducted at Roche to update and enhance our internal chemogenomics compound library. Chemogenomics describes the connection between chemical compounds and their activities on biological targets. To study chemogenomics, one tool can be a chemical library of compounds with well defined biological activity, which can be built either by target-based screening or literature review. Such a library can be used to find targets and mechanisms of action of observed phenotypes, to identify so far unknown links in biology or pinpoint previously unknown target activity for compounds in the library. Roche?s inhouse chemogenomic library is called Pathway-Annotated Chemical Ensemble (PACE). In the past two years, together with our colleagues at Genentech, we have worked on enriching the previous version of the PACE library by adding new compounds, complementing existing annotations, assessing the sample quality and standardising target and gene names. As a result, a new PACE library version 2022 is now available for screening for Roche portfolio projects and collaborations.
Biological Sample Management AND Pre-competitive Collaboration and Sharing of Samples
Automation as a prerequisite for sample quality in the Leipzig Medical Biobank
Open to view video.
Open to view video. Biobanks are important infrastructures to support clinical research and developments in personalized medicine. Quality-assured collection, processing and storage of biological samples with defined pre-analytical history plays a key role for reproducibility in scientific research and paves the path towards precision medicine. Due to the increasing need for large numbers of samples, both in basic as well as in translational research, particular attention must be paid to sample acquisition and preparation to guarantee the highest possible sample quality. Automation of critical process steps in biobanking can help to reach the highest quality standard and consistent sample quality. The Leipzig Medical Biobank (LMB) at the University Leipzig is a state-of-the-art biobank for the quality-assured collection, processing, storage and provision of biospecimens. Founded in 2010, it initially collected, processed, stored and made available for research projects mainly liquid samples such as urine, serum, plasma and saliva from epidemiological studies of the Leipzig Research Centre for Civilisation Diseases (LIFE). In 2017 healthcare integrated biobanking was started with clinical partners and the Institutes of Pathology and Laboratory Medicine. The samples are processed in a highly standardised and traceable manner and stored predominantly at temperatures of -80°C or <-150°C in the gas phase of liquid nitrogen. Storage is carried out in strict compliance with an uninterrupted cold chain and constant monitoring. All samples are identified by a barcode and can thus be linked to quality-relevant data such as processing and storage times as well as to clinical data of the donor. This means that extensive data sets are also available for the samples. Automated solutions are used for different parts of the lifecycle of the samples. In order to keep the quality high, all processes are validated and well documented in standardized operating procedures in our quality management system.
Sample Management beyond small molecules
Open to view video.  |   Closed captions available
Open to view video.  |   Closed captions available In the last few years, the pharmaceutical research landscape has changed. Small molecule compounds are no longer the main source of new drugs and we are seeing significant changes in drug modality. With this comes increasing challenges but also significant opportunities for Sample Management organisations to help support this changing landscape. Sample Management at GlaxoSmithKline is in the final stages of a large global modernisation strategy. This presentation will cover the infrastructure and process changes needed to effectively support the biological portfolios, focusing mainly on the Biopharma monoclonal antibody (mAbs)space. GlaxoSmithKline will share how the Sample Management changes link into a new overarching Biopharma automation strategy. The presentation will provide detail around the new Sample Management modality agnostic liquid handling automation, the new workflows and processes, and share some adopted best practices. The implementation of these new Sample Management mAbs workflows has not been without its challenges and these will be shared along with the solutions adopted to overcome them.
Pre-Competitive Collaboration and Sharing of Samples
Open to view video.  |   Closed captions available
Open to view video.  |   Closed captions available
Shared Libraries: The Success Story of the European Lead Factory
Open to view video.  |   Closed captions available
Open to view video.  |   Closed captions available
Roundtable Discussion: Accessing the Universe of 'Actionable' Chemical Space to Enhance Compound Collections
Roundtable Discussion: Accessing the Universe of 'Actionable' Chemical Space to Enhance Compound Collections
Open to view video.  |   Closed captions available
Open to view video.  |   Closed captions available Chemical space is vast and counts more than 10^63 molecules. Only a tiny fraction of them can be accessed synthetically. Among many reported approaches, Enamine REAL allows to access billions of make-on-demand molecules which are delivered to stock within 3-4 weeks with over 80% success rate. The REAL approach is based on an application of thoroughly validated synthetic procedures to the validated in-stock building blocks and reagents. The REAL approach has become a popular resource among researchers who are interested in accessing large chemical space to find hits and/or new chemotypes and thus advance their projects.